Last reviewed · How we verify
Apraclonidine Hydrochloride Ophthalmic Solution
At a glance
| Generic name | Apraclonidine Hydrochloride Ophthalmic Solution |
|---|---|
| Also known as | FID 123320 |
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Conjunctival blanching
- Upper lid elevation
- Mydriasis
- Burning
- Discomfort
- Foreign body sensation
- Dryness
- Itching
- Blurred or dimmed vision
- Allergic response
- Conjunctival microhemorrhage
- Abdominal pain
Serious adverse events
- Vasovagal attack
- Orthostatic episode
- Hypotony
- Ocular injection
- Irregular heart rate
- Ocular inflammation
- Shortness of breath
- Chest heaviness or burning
- Hypersensitivity
- Decreased libido
Key clinical trials
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness (PHASE3)
- Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: